JP Morgan Chase
GANX icon

JP Morgan Chase’s Gain Therapeutics GANX Stock Holding History

JP Morgan Chase’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.37K Hold
1,700
– – ﹤0.01% 7141
2026
Q1 		$3.06K Buy
+1,700
New +$3.7K ﹤0.01% 6950
2025
Q4 		– Sell
-26,280
Closed -$46.5K – 7543
2025
Q3 		$46.5K Buy
+26,280
New +$44.3K ﹤0.01% 6257
2023
Q3 		– Sell
-6
Closed -$27 – 7551
2023
Q2 		$27 Buy
+6
New +$29 ﹤0.01% 6774
2022
Q4 		– Sell
-594
Closed -$2K – 6708
2022
Q3 		$2K Buy
+594
New +$2.23K ﹤0.01% 6249

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

JP Morgan Chase's GANX Position: Q2 2026 in Review

JP Morgan Chase held its Gain Therapeutics (GANX) position steady in Q2 2026 at 1,700 shares worth $3.37K. The position accounts for ﹤0.01% of the portfolio, ranked #7141.

JP Morgan Chase first reported a position in GANX in Q3 2022 and has held it in 5 quarters since. The position peaked at $46.5K in Q3 2025. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • JP Morgan Chase held 1,700 shares of Gain Therapeutics worth $3.37K as of Q2 2026.
  • JP Morgan Chase left its Gain Therapeutics share count unchanged in Q2 2026.
  • Gain Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7141 holding.
  • JP Morgan Chase first reported a position in Gain Therapeutics in Q3 2022 and has held it in 5 quarters since.
  • JP Morgan Chase's Gain Therapeutics position peaked at $46.5K in Q3 2025.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.